31 July 2020 : Clinical Research
Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma
Ying Yang1AEF, Zhuogang Liu1ABC, Hongtao Wang1ACEG*DOI: 10.12659/MSM.923716
Med Sci Monit 2020; 26:e923716
Table 1 The relationship between ALC and prognostic factors (P<0.05).
| Characteristics | Low ALC groupALC <1.43×109/L | High ALC groupALC ≥1.43×109/L | P-value |
|---|---|---|---|
| Sex | 0.297 | ||
| Male | 36 | 31 | |
| Female | 15 | 20 | |
| Age, y | 0.003 | ||
| <60 | 17 | 32 | |
| ≥60 | 34 | 19 | |
| BMI, kg/m | 0.992 | ||
| <22.85 | 20 | 22 | |
| ≥22.85 | 21 | 23 | |
| DS staging | 0.13 | ||
| Stage I | 1 | 6 | |
| Stage II | 7 | 8 | |
| Stage III | 43 | 37 | |
| Group A | 31 | 43 | 0.008 |
| Group B | 20 | 8 | |
| ISS staging | 0.007 | ||
| Stage I | 1 | 4 | |
| Stage II | 12 | 24 | |
| Stage III | 38 | 23 | |
| ISS dichotomy | 0.002 | ||
| Early stage | 13 | 28 | |
| Late stage | 38 | 23 | |
| L-ISS staging | <0.001 | ||
| Stage I | 0 | 5 | |
| Stage II | 12 | 44 | |
| Stage III | 39 | 2 | |
| L-ISS dichotomy | <0.001 | ||
| Early stage | 12 | 49 | |
| Late stage | 39 | 2 | |
| M-fraction type | 0.644 | ||
| IgG | 24 | 25 | |
| IgA | 8 | 12 | |
| Light chain | 14 | 12 | |
| Light chain type | 0.231 | ||
| κ | 24 | 31 | |
| lambda; | 24 | 19 | |
| HGB, g/L | <0.001 | ||
| <100 | 44 | 27 | |
| ≥100 | 7 | 24 | |
| PLT | 0.038 | ||
| <135×10/L | 23 | 13 | |
| ≥135×10/L | 28 | 38 | |
| LDH, U/L | 0.971 | ||
| <243 | 29 | 31 | |
| ≥243 | 20 | 22 | |
| β2-MG, mg/L | 0.004 | ||
| <5.5 | 11 | 25 | |
| ≥5.5 | 37 | 24 | |
| ALB, g/L | 0.19 | ||
| <35 | 35 | 29 | |
| ≥35 | 16 | 22 | |
| Ca, mmol/L | 0.065 | ||
| <2.75 | 48 | 42 | |
| ≥2.75 | 3 | 9 | |
| IgG dichotomy, g/L | 0.26 | ||
| <70 | 17 | 14 | |
| ≥70 | 6 | 10 | |
| IgA dichotomy, g/L | 0.848 | ||
| <50 | 5 | 8 | |
| ≥50 | 3 | 4 |